Retifanlimab as first-line treatment for locally recurrent or metastatic squamous cell carcinoma of the anal canal (PubMed, Bull Cancer) - Sep 1, 2026 - No abstract available
Journal • Anal Carcinoma • Oncology • Squamous Cell Carcinoma
|
|
Adnan Antoine Shrebati; Stanislas Quesada
|